Chronic hand eczema - Pipeline Insight, 2024

Chronic hand eczema - Pipeline Insight, 2024

DelveInsight’s, Chronic hand eczema - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic hand eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.



Geography Covered

• Global coverage

Chronic hand eczema Understanding

Chronic hand eczema: Overview

Hand eczema is a very common and widespread condition, which was presumably first described in the 19th century. It is a frequently encountered problem, affecting individuals of various occupations. Variety of factors may take part in the causation of this condition including endogenous and external/environmental factors acting either singly or in combination. In the 19th century, dermatologists described several morphological variants of hand eczema such as eczema solare, rubrum, impetiginoides, squamosum, papulosum, and marginatum. Chronic hand eczema (CHE) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Topical therapeutics comprise the standard of care, but up to 65% of cases do not resolve after treatment, and moderate-to-severe cases are often resistant to topical therapeutics and require systemic options instead.

""Chronic hand eczema - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic hand eczema pipeline landscape is provided which includes the disease overview and Chronic hand eczema treatment guidelines. The assessment part of the report embraces, in depth Chronic hand eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic hand eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic hand eczema R&D. The therapies under development are focused on novel approaches to treat/improve Chronic hand eczema.

This segment of the Chronic hand eczema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic hand eczema Drugs

• ARQ-252: Arcutis Biotherapeutics

ARQ-252 is a topical janus kinase 1 (JAK1) inhibitor that has promise as a novel treatment for inflammatory dermatologic diseases, including chronic hand eczema and vitiligo. Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and atopic dermatitis. ARQ-252 is differentiated from other topical JAK inhibitors by its high potency and unique high selectivity against JAK1 compared to JAK2. ARQ-252’s selectivity for JAK1 may confer important safety advantages compared to other topical JAK inhibitors.

• ASN002: Asana BioSciences

ASN002 (Gusacitinib) is a potent dual inhibitor of JAK and SYK kinases, which are involved in both cytokine production and signaling. ASN002 inhibits JAK-mediated cytokine signaling and JAK-SYK mediated T- and B-cell proliferation and function. Gusacitinib completed Phase 2 clinical evaluation in moderate-to-severe chronic hand eczema (CHE) patients.

Further product details are provided in the report……..

Chronic hand eczema: Therapeutic Assessment

This segment of the report provides insights about the Chronic hand eczema drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic hand eczema

There are approx. 5+ key companies which are developing the therapies for Chronic hand eczema. The companies which have their Chronic hand eczema drug candidates in the most advanced stage, i.e. Phase III include Arcutis Biotherapeutics.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic hand eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic hand eczema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic hand eczema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic hand eczema drugs.

Chronic hand eczema Report Insights

• Chronic hand eczema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic hand eczema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic hand eczema drugs?
• How many Chronic hand eczema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic hand eczema?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic hand eczema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic hand eczema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcutis Biotherapeutics
• Asana BioSciences

Key Products

• ARQ-252
• ASN002